Nimotuzumab(Synonyms: 尼妥珠单抗)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Nimotuzumab (Synonyms: 尼妥珠单抗) 纯度: 96.30%

Nimotuzumab 是一种靶向 EGFR 的人源化 IgG1 单克隆抗体，KD 为 0.21 nM。Nimotuzumab 针对 EGFR 的细胞外结构域，阻断与其配体的结合。Nimotuzumab 是一种强抗肿瘤药物，通过其引起抗体依赖性细胞介导的细胞毒性 (ADCC) 和补体依赖性细胞毒性(CDC) 的能力，对靶肿瘤具有溶细胞作用。

Nimotuzumab(Synonyms: 尼妥珠单抗)

Nimotuzumab Chemical Structure

CAS No. : 780758-10-3

规格 价格 是否有货 数量
1 mg ￥5600 In-stock
5 mg ￥19500 In-stock
10 mg   询价  
50 mg   询价  

* Please select Quantity before adding items.

生物活性

Nimotuzumab is a humanized IgG1 monoclonal antibody targeting EGFR with a KD of 0.21 nM. Nimotuzumab is directed against the extracellular domain of the EGFR blocking the binding to its ligands. Nimotuzumab, a strong antitumor drug, is cytolytic on target tumors by its capacity to cause antibody dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC)[1][2].

体外研究
(In Vitro)

Nimotuzumab (10 μg/mL; 24 hours) induces significant downregulation of CD16 on NK cells[1].
Nimotuzumab (10 μg/mL; 48 hours) induces the upregulation of PD-L1 molecule on DCs when co-cultured with the NK: DC: HNSCC cells[1].
The intrinsic properties of Nimotuzumab requires bivalent binding (i.e., binding with both antibody arms to two targets simultaneously) for stable attachment to cellular surface, which leads to Nimotuzumab selectively binding to cells that express moderate to high EGFR levels[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial

CAS 号

780758-10-3
中文名称

尼妥珠单抗
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Zaima Mazorra, et al. Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients. Front Pharmacol. 2017 Jun 19;8:382.

    [2]. Melarkode S Ramakrishnan, et al. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. MAbs. Jan-Feb 2009;1(1):41-8.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务